5df9

Publication Abstract from PubMed

Penicillin-binding protein 3 (PBP3) from Pseudomonas aeruginosa is the molecular target of beta-lactam-based antibiotics. Structures of PBP3 in complexes with azlocillin and cefoperazone, which are in clinical use for the treatment of pseudomonad infections, have been determined to 2.0 A resolution. Together with data from other complexes, these structures identify a common set of residues involved in the binding of beta-lactams to PBP3. Comparison of wild-type and an active site mutant (S294A) showed that increased thermal stability of PBP3 following azlocillin binding was entirely due to covalent binding to S294, whereas cefoperazone binding produces some increase in stability without the covalent link. Consistent with this, a third crystal structure was determined in which the hydrolysis product of cefoperazone was noncovalently bound in the active site of PBP3. This is the first structure of a complex between a penicillin-binding protein and cephalosporic acid and may be important in the design of new noncovalent PBP3 inhibitors.

Crystal structures of penicillin-binding protein 3 in complexes with azlocillin and cefoperazone in both acylated and deacylated forms.,Ren J, Nettleship JE, Males A, Stuart DI, Owens RJ FEBS Lett. 2016 Jan;590(2):288-97. doi: 10.1002/1873-3468.12054. Epub 2016 Jan, 23. PMID:26823174^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.